Business & FinanceDealsHealth 14 July 2023, 5:43 pm 1 minute MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition. Market Impact MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday,…
Business & FinanceDealsHealth 14 July 2023, 5:43 pm 1 minute MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition. Market Impact MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday,…
Business & FinanceDealsHealth 14 July 2023, 5:43 pm 1 minute MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition. Market Impact MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday,…
Business & FinanceDealsHealth 14 July 2023, 5:43 pm 1 minute MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition. Market Impact MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday,…
Business & FinanceDealsHealth 14 July 2023, 5:43 pm 1 minute MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition. Market Impact MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday,…
Health 11 July 2023, 5:39 pm 1 minute Reuters exclusively reported that Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s (NOVOb.CO) Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply. Market Impact Shares of the Danish drugmaker fell 2.3% on Tuesday. Article…
Health 11 July 2023, 5:39 pm 1 minute Reuters exclusively reported that Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s (NOVOb.CO) Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply. Market Impact Shares of the Danish drugmaker fell 2.3% on Tuesday. Article…
Planning focused more on burying the dead than averting disaster, ex-health secretary says.
Sir Chris laments treatment as he gives evidence to Covid Inquiry on pandemic preparedness.
The UK should have prepared to test and isolate more, the ex-health secretary tells the Covid inquiry.
